<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>9985</td>
<td>Role of short chain fatty acids in gut health and possible therapeutic approaches in inflammatory bowel diseases</td>
<td>Caetano MAF, Castelucci P</td>
</tr>
<tr>
<td>1004</td>
<td>Review of the pharmacological effects of astragaloside IV and its autophagic mechanism in association with inflammation</td>
<td>Yang Y, Hong M, Lian WW, Chen Z</td>
</tr>
<tr>
<td>10031</td>
<td>Analysis of the successful clinical treatment of 140 patients with parathyroid adenoma: A retrospective study</td>
<td>Peng ZX, Qin Y, Bai J, Yin JS, Wei BJ</td>
</tr>
<tr>
<td>10042</td>
<td>Efficacy of digital breast tomosynthesis combined with magnetic resonance imaging in the diagnosis of early breast cancer</td>
<td>Ren Y, Zhang J, Zhang JD, Xu JZ</td>
</tr>
<tr>
<td>10053</td>
<td>Prevention and management of adverse events following COVID-19 vaccination using traditional Korean medicine: An online survey of public health doctors</td>
<td>Kang B, Chu H, Youn BY, Leem J</td>
</tr>
<tr>
<td>10066</td>
<td>Clinical outcomes of targeted therapies in elderly patients aged ≥ 80 years with metastatic colorectal cancer</td>
<td>Jang HR, Lee HY, Song SY, Lim KH</td>
</tr>
<tr>
<td>10077</td>
<td>Endovascular treatment vs drug therapy alone in patients with mild ischemic stroke and large infarct cores</td>
<td>Kou WH, Wang XQ, Yang JS, Qiao N, Nie XH, Yu AM, Song AX, Xue Q</td>
</tr>
</tbody>
</table>
**Clinical Trials Study**

10085  One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C


**Observational Study**

10097  Dementia-related contact experience, attitudes, and the level of knowledge in medical vocational college students


**SYSTEMATIC REVIEWS**

10109  Link between COVID-19 vaccines and myocardial infarction

Zafar U, Zafar H, Ahmed MS, Khattak M

**CASE REPORT**

10120  Successful treatment of disseminated nocardiosis diagnosed by metagenomic next-generation sequencing: A case report and review of literature

Li T, Chen YX, Lin JJ, Lin WX, Zhang WZ, Dong HM, Cai SX, Meng Y

10130  Multiple primary malignancies – hepatocellular carcinoma combined with splenic lymphoma: A case report

Wu FZ, Chen XX, Chen WY, Wu QH, Mao JT, Zhao ZW

10136  Metastatic multifocal melanoma of multiple organ systems: A case report


10146  Cavernous hemangioma of the ileum in a young man: A case report and review of literature

Yao L, Li LW, Yu B, Meng XD, Liu SQ, Xie LH, Wei RF, Liang J, Ruan HQ, Zou J, Huang JA

10155  Successful management of a breastfeeding mother with severe eczema of the nipple beginning from puberty: A case report

Li R, Zhang LX, Tian C, Ma LK, Li Y

10162  Short benign ileocolonic anastomotic strictures - management with bi-flanged metal stents: Six case reports and review of literature

Kasapidis P, Mavrogenis G, Mandrekas D, Bazerbachi F

10172  Simultaneous bilateral floating knee: A case report

Wu CM, Liao HE, Lan SJ

10180  Chemotherapy, transarterial chemoembolization, and nephrectomy combined treated one giant renal cell carcinoma (T3aN1M1) associated with Xp11.2/TFE3: A case report


10186  Tislelizumab-related enteritis successfully treated with adalimumab: A case report

Chen N, Qian MJ, Zhang RH, Gao QQ, He CC, Yao YK, Zhou JY, Zhou H
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>10193</td>
<td>Treatment of refractory/relapsed extranodal NK/T cell lymphoma with decitabine plus anti-PD-1: A case report</td>
<td>Li LJ, Zhang JY</td>
</tr>
<tr>
<td>10201</td>
<td>Clinical analysis of pipeline dredging agent poisoning: A case report</td>
<td>Li YQ, Yu GC, Shi LK, Zhao LW, Wen ZX, Kan BT, Jian XD</td>
</tr>
<tr>
<td>10214</td>
<td>Twin reversed arterial perfusion sequence-a rare and dangerous complication form of monochorionic twins: A case report</td>
<td>Anh ND, Thu Ha NT, Sim NT, Toan NK, Thuong PTH, Duc NM</td>
</tr>
<tr>
<td>10220</td>
<td>Potential otogenic complications caused by cholesteatoma of the contralateral ear in patients with otogenic abscess secondary to middle ear cholesteatoma of one ear: A case report</td>
<td>Zhang L, Niu X, Zhang K, He T, Sun Y</td>
</tr>
<tr>
<td>10236</td>
<td>Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report</td>
<td>Xu SZ, Zhang XC, Jiang Q, Chen M, He MY, Shen P</td>
</tr>
<tr>
<td>10252</td>
<td>Persistent diarrhea with petechial rash - unusual pattern of light chain amyloidosis deposition on skin and gastrointestinal biopsies: A case report</td>
<td>Bilton SE, Shah N, Dougherty D, Simpson S, Holliday A, Sahebjam F, Grider DJ</td>
</tr>
<tr>
<td>10260</td>
<td>Solitary splenic tuberculosis: A case report</td>
<td>Guo HW, Liu XQ, Cheng YL</td>
</tr>
<tr>
<td>10266</td>
<td>Coronary artery aneurysms caused by Kawasaki disease in an adult: A case report and literature review</td>
<td>He Y, Ji H, Xie JC, Zhou L</td>
</tr>
<tr>
<td>10273</td>
<td>Double filtration plasmapheresis for pregnancy with hyperlipidemia in glycogen storage disease type Ia: A case report</td>
<td>Wang J, Zhao Y, Chang P, Liu B, Yao R</td>
</tr>
<tr>
<td>10279</td>
<td>Treatment of primary tracheal schwannoma with endoscopic resection: A case report</td>
<td>Shen YS, Tian XD, Pan Y, Li H</td>
</tr>
<tr>
<td>10286</td>
<td>Concrescence of maxillary second molar and impacted third molar: A case report</td>
<td>Su J, Shao LM, Wang LC, He LJ, PuYL, Li YB, Zhang WY</td>
</tr>
</tbody>
</table>
Contents

Thrice Monthly Volume 10 Number 28 October 6, 2022

10293 Rare leptin in non-alcoholic fatty liver cirrhosis: A case report
Nong YB, Huang HN, Huang JJ, Du YQ, Song WX, Mao DW, Zhong YX, Zhu RH, Xiao XY, Zhong RX

10301 One-stage resection of four genotypes of bilateral multiple primary lung adenocarcinoma: A case report

10310 Ectopic pregnancy and failed oocyte retrieval during *in vitro* fertilization stimulation: Two case reports
Zhou WJ, Xu BF, Niu ZH

10317 Malignant peritoneal mesothelioma with massive ascites as the first symptom: A case report
Huang X, Hong Y, Xie SY, Liao HL, Huang HM, Liu JH, Long WJ

10326 Subperiosteal orbital hematoma concomitant with abscess in a patient with sinusitis: A case report
Hu XH, Zhang C, Dong YK, Cong TC

10332 Postpartum posterior reversible encephalopathy syndrome secondary to preeclampsia and cerebrospinal fluid leakage: A case report and literature review
Wang Y, Zhang Q

10339 Sudden extramedullary and extranodal Philadelphia-positive anaplastic large-cell lymphoma transformation during imatinib treatment for CML: A case report

10346 Relationship of familial cytochrome P450 4V2 gene mutation with liver cirrhosis: A case report and review of the literature

10358 COVID-19-associated disseminated mucormycosis: An autopsy case report

10366 Thalidomide combined with endoscopy in the treatment of Cronkhite-Canada syndrome: A case report
Rong JM, Shi ML, Niu JK, Luo J, Miao YL

10375 Thoracolumbar surgery for degenerative spine diseases complicated with tethered cord syndrome: A case report
Wang YT, Mu GZ, Sun HL

LETTER TO THE EDITOR

10384 Are pregnancy-associated hypertensive disorders so sweet?
Thomopoulos C, Ilias I

10387 Tumor invasion front in oral squamous cell carcinoma
Cuevas-González JC, Cuevas-González MV, Espinosa-Cristobal LF, Donohue Cornejo A
ABOUT COVER
Editorial Board Member of *World Journal of Clinical Cases*, Kaleem Ullah, FCPS, MBBS, Assistant Professor, Solid Organ Transplantation and Hepatobiliary Surgery, Pir Abdul Qadir Shah Jeelani Institute of Medical Sciences, Gambat 66070, Sindh, Pakistan. drkaleempk@gmail.com

AIMS AND SCOPE
The primary aim of *World Journal of Clinical Cases* (*WJCC, World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

*WJCC* mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING
The *WJCC* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for *WJCC* as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The *WJCC*’s CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Xu Guo; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL
*World Journal of Clinical Cases*

ISSN
ISSN 2307-8960 (online)

LAUNCH DATE
April 16, 2013

FREQUENCY
Thrice Monthly

EDITORS-IN-CHIEF
Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyun Ku

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2307-8960/editorialboard.htm

PUBLICATION DATE
October 6, 2022

COPYRIGHT
© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Treatment of refractory/relapsed extranodal NK/T cell lymphoma with decitabine plus anti-PD-1: A case report

Lin-Jie Li, Jun-Yu Zhang

Specialty type: Hematology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report’s scientific quality classification
Grade A (Excellent): A, A
Grade B (Very good): B, B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Ekine-Afolabi B, United Kingdom; Hashimoto K, Japan

Received: April 9, 2022
Peer-review started: April 9, 2022
First decision: June 16, 2022
Revised: June 24, 2022
Accepted: August 24, 2022
Article in press: August 24, 2022
Published online: October 6, 2022

Abstract

BACKGROUND
Extranodal natural killer/T cell lymphoma, nasal type (ENKL) is a highly aggressive malignancy characterized by its association with Epstein-Barr virus (EBV) and extranodal involvement, which shows a poor clinical outcome. Although L-asparaginase-based chemotherapy has improved the response rates of relapsed/refractory (R/R) ENKL, relapse occurs in up to 50% of patients with disseminated disease.

CASE SUMMARY
Immune evasion has emerged as a critical pathway for survival in ENKL and may be effectuated via STAT3-driven upregulation of programmed cell death ligand 1 (PD-L1) or other molecular pathways. Anti-PD-1 is effective for R/R ENKL with EBV-driven upregulation of PD-L1 expression. Anti-PD-1 combined with decitabine showed positive preliminary results in a patient with R/R ENKL and resistance to anti-PD-1.

CONCLUSION
The treatment experience, in this case, demonstrated the potential ability of decitabine combined with PD-1 inhibitor to treat R/R ENKL, thus providing a new treatment strategy for this tumor.

Key Words: NK-T cell lymphoma; Refractory/relapsed; Anti-PD-1; Decitabine; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: Extranodal natural killer/T cell lymphoma nasal type is a highly aggressive malignancy characterized by its association with Epstein-Barr virus and extranodal involvement, which shows a poor clinical outcome. Now, we report a rare case of relapsed/refractory classic Hodgkin lymphoma with resistance to anti-PD-1 in which anti-PD-1 combined with decitabine showed positive preliminary results. Our findings support the potential benefit of anti-PD-1 combined with decitabine in this type of refractory T-cell lymphoma.

INTRODUCTION

Extranodal natural killer/T cell lymphoma (ENKL) is a rare T-cell lymphoma with a poor prognosis and poor response to conventional chemotherapy. ENKL is more prevalent in China than in Western countries[1,2]. It is a highly aggressive lymphoma with poor efficacy and prognosis by traditional treatments[3,4]. The treatment options for relapsed/refractory (R/R) ENKL are still limited, and improving the treatment is an urgent requirement. Some studies have shown that ENKL cells avoid immune surveillance and the consequent killing of ENKL, resulting in a poor outcome[5].

CASE PRESENTATION

Chief complaints
A 54-year-old male patient was admitted to our hospital with a diagnosis of ENKL for > 4 years.

History of present illness
About 4 years ago, the patient visited our hospital for recurrent gingival bleeding accompanied by night sweats and a recent weight loss of > 10 kg. Positron emission tomography/computed tomography (PET/CT) showed multiple lymphadenopathies in the bilateral neck and supraclavicular area (especially in the right neck), strip-shaped soft tissue density shadow in the right nasal cavity, and significantly increased fluorodeoxyglucose (FDG) metabolism (Figure 1). Biopsy of the right nasal septum mucosa was performed postoperatively, and the pathology showed ENKL. Immunohistochemistry showed CD3 +, CD4 +, CD56 +, granzyme B +, CD8 -, CD20 -, Pax5 -, and Ki-67 + (about 80%). Molecular in situ hybridization demonstrated positivity for EBER (Figure 2).

History of past illness
The patient had no history of past illness.

Personal and family history
No personal or family history was available.

Physical examination
There were multiple lymphadenectasis in the bilateral neck especially in the right neck. No palpable enlargement of the liver or spleen was noted.

Laboratory examinations
The liver function, renal function, routine blood tests, myocardial enzymes, and coagulation function were normal. Bone marrow puncture was not performed.

Imaging examinations
On March 3, 2018, PET/CT showed multiple lymphadenopathies in the bilateral neck and supraclavicular area (especially in the right neck), strip-shaped soft tissue density shadow in the right nasal cavity, and significantly increased FDG metabolism and a high standard uptake value (SUV) with a Deauville score of 7.6 (Figure 1).

On June 6, 2017, PET/CT showed that the original lesions in the right nasal cavity, bilateral neck, and supraclavicular area had subsided and become inactive compared to the scan on March 3, 2017. However, there was new large, curved wall thickening of the gastric body, multiple nodules of the
spleen, multiple lymphadenopathies around the stomach, mediastinum and left hilum, and increased FDG metabolism (Figure 3).

On November 9, 2021, PET/CT showed that right mediastinal paratracheal, right main bronchial, and subcarinal lymph nodes and ilioceleal small nodules subsided and became inactive, and the metabolism of left lower lobe nodules was decreased significantly (SUVmax decreased from 10.2 to 3.8) (Figure 4).

**FINAL DIAGNOSIS**

According to the above medical history, the final diagnosis was ENKL.

**TREATMENT**

After diagnosis, the patient was given SMILE regimen for two cycles (methotrexate 4.5 g d1, dexamethasone 40 mg d1–4, ifosfamide 2 g d2–4, etoposide 160 mg d2–4, L-asparaginase 3200 U d5) on March 10 and April 8, 2017, respectively. Since May 2, 95% planned target volume at 54Gy/28f was irradiated to the local lesion and irregular large-area fields on both sides of the neck. PET/CT on June 6, 2017 showed that the original lesions in the right nasal cavity, bilateral neck, and supraclavicular area have subsided and become inactive compared to the scan on March 3, 2017. However, there was new large, curved wall thickening of the gastric body, multiple nodules of the spleen, multiple lymphadenopathies around the stomach, mediastinum, and left hilum, and increased FDG metabolism (Figure 3). Gastroscopic pathological biopsy suggested ENKL. Then, DDGP regimen plus methotrexate (gemcitabine 1.63 g d1 and 8, methotrexate 3.20 g d1–4, dexamethasone 30 mg d1–4, L-asparaginase 3750 U d5) chemotherapy was administered for two cycles. On August 30, after SMILE regimen was repeated, stem cells were prepared for autologous stem cell transplantation, but the collection failed. On October 27, modified SMILE regimen (dexamethasone 32 mg d1–4, etoposide 100 mg d2–4, methotrexate 3.6 g d1, L-asparaginase 3750 U d5) chemotherapy was administered. Compared to June 6, 2017, the PET/CT on November 17 showed that the original lesions of the left lung, great curvature of the gastric body, perigastric, spleen, mediastinum, and left hilum had subsided and become inactive, but there were new lesions on the pancreatic head and right lung, with increased FDG metabolism. The patient revisited our hospital, and he was considered with refractory lymphoma. Thus, pembrolizumab 200 mg was administered every 21 d. The follow-up PET/CT after 6 mo showed complete remission of lymphoma. So, the maintenance treatment was continued for > 2 years. However, in July 2021, PET/CT
Li LJ et al. Treatment of refractory/relapsed ENKL

Figure 2 Molecular in situ hybridization demonstrated positivity for EBER. A: Tumor cells are large, nucleus pleomorphic or elongated, deeply stained, diffuse, and patchy (hematoxylin-eosin staining, ×400); B: EBER positivity (in situ hybridization, ×400); C: CD3 positivity (Envision two-step immunohistochemical staining, ×400); D: CD56-positivity (Envision two-step immunohistochemical staining, ×400); E: Granzyme B positivity (Envision two-step immunohistochemical staining, ×400); F: Ki-67 positive expression rate of 80%.

Figure 2 Molecular in situ hybridization demonstrated positivity for EBER. A: Tumor cells are large, nucleus pleomorphic or elongated, deeply stained, diffuse, and patchy (hematoxylin-eosin staining, ×400); B: EBER positivity (in situ hybridization, ×400); C: CD3 positivity (Envision two-step immunohistochemical staining, ×400); D: CD56-positivity (Envision two-step immunohistochemical staining, ×400); E: Granzyme B positivity (Envision two-step immunohistochemical staining, ×400); F: Ki-67 positive expression rate of 80%.

showed that the right mediastinal paratracheal, right main bronchial, and subcarinal lymph nodes (groups 4R, 10R, and 7) were further enlarged. New nodules were added in the lower lobe of the left lung, and small nodules were added in the ileocecal part; all had significantly increased FDG metabolism (Figure 4). However, no tumor cells were found in the alveolar lavage fluid and bronchoscopic biopsy. Combined with the medical history and clinical presentation, this patient was considered with relapsed ENKL, and AspaMetDex regimen chemotherapy (methotrexate 3 g d1, dexamethasone 40 mg d1–4, L-asparaginase 3400 U d5) combined with chidamide 30 mg orally twice a week was used. Repeat CT showed that the lesions in the lower lobe of the left lung increased in size after two cycles. As the disease progressed, we utilized the regimen of decitabine 25 mg d1–5, sintilimab 200 mg d6, and L-asparaginase 3750 U d10 for combined chemotherapy.

OUTCOME AND FOLLOW-UP

The above scheme was repeated after 4 wk. PET/CT on July 16, 2021 showed that after 8 wk, the right mediastinal paratracheal, right main bronchial, subcarinal lymph nodes, and small ileocecal nodules subsided and were inactive, and the left lower lobe nodules, and FDG metabolism decreased significantly (Figure 4). This patient is still undergoing regular chemotherapy every 4 wk: Decitabine 25 mg d1–5, sintilimab 200 mg d6, and L-asparaginase 3750 U d10. To the best of our knowledge, this is the first case of decitabine combined with anti-PD-1 applied to R/R ENKL.
DISCUSSION

As an inhibitory receptor, PD-1, expressed on the surface of activated T cells, is involved in immune tolerance and the prevention of tissue damage associated with chronic inflammation. Inflammatory cytokines have been found to induce programmed cell death ligand 1 (PD-L1) expression in many studies. In particular, the involvement of IFN-γ in immune checkpoint induction has been reported. When the expression of proinflammatory cytokines was high, it suggests the possibility that the expression of PD-L1 Therefore, it suggests the possibility that the expression of PD-L1

PD-1 interacts with its ligands PD-L1 and PD-L2 to inhibit T cell receptor signal, downregulate T cell activation and proliferation, and weaken the T cell-mediated anti-tumor immune response[7,8]. Therefore, the PD-1 pathway is an immune checkpoint that suppresses anti-tumor immunity. Other studies have reported the efficacy of anti-PD-1 in R/R ENKL[5,9].

Exhausted T cells, including memory-like exhausted T cells that respond to PD-1 inhibitors, ultimately differentiate into terminal exhausted T cells. These T cells are resistant to anti-PD-1-induced rejuvenation but can still exhibit distinct epigenetic profiles[10-12]. Another study identified low-dose DNA demethylating agents that alter T-cell’s epigenetic status and enhance the anti-tumor activity of PD-1/PD-L1 blockade therapy in mouse models[13,14]. Reportedly, T cell phenotype and function and the expression of PD-1 are strongly regulated by epigenetic changes[15,16]. Patients with hematological malignancies treated with hypomethylating agents have demonstrated increased expression of PD-1 transcripts and proteins on the cell surface[17,18]. With the expanding application of immune checkpoint inhibitors in hematological malignancies, immunotherapies targeting the PD-1/PD-L1 axis combined with hypomethylating agents may counteract the upregulation of PD-1/PD-L1 checkpoints and improve the clinical outcomes[18]. While anti-PD-1 alone had modest effects, hypomethylating agents followed by anti-PD-1 therapy inhibited tumor growth and prolonged the survival of the pancreatic cancer mouse model[19]. Wang et al[20] found that decitabine combined with anti-PD-1 achieves curative effects in patients with R/R Hodgkin’s lymphoma resistant to anti-PD-1 and is a safe and feasible approach. A randomized phase II study of R/R Hodgkin’s lymphoma demonstrated that anti-PD-1 plus decitabine was well-tolerated and improved the clinical outcomes compared to anti-PD-1 alone with regard to the duration of response (DOR) and progression-free survival (PFS)[21]. The common treatment-related adverse events, such as a benign and reversible skin condition, reactive capillary endothelial proliferation, and leukocytopenia, but no treatment-related infections, were identified[21]. Although this protocol has achieved good preliminary results in Hodgkin’s lymphoma and other tumors, this is the first attempt to use this combination therapy in R/R ENKL. Our patient was resistant to pembrolizumab after continual treatment for 2 years but still achieved near-complete
Li LJ et al. Treatment of refractory/relapsed ENKL

Figure 4 Positron emission tomography/computed tomography images. A-C: Compared to the film on July 16, 2021, that taken on November 9, 2021 showed that right mediastinal paratracheal, right main bronchial, subcarinal lymph nodes and ileocecal small nodules had subsided and become inactive, and the metabolism of left lower lobe nodules was decreased significantly (SUVmax decreased from 10.2 to 3.8).

remission by decitabine combined with sintilimab. Although the binding sites of the two antibodies are different, more over the Fc side of sintinib was modified to avoid direct phagocytosis of antibody molecules. These mechanisms maybe result in the different response between these two antibodies. But as far as the current research is concerned, sintilimab has similar anti-tumor effects to other anti-PD-1 [22]. No treatment-related adverse events were noted in our case.

L-asparaginase-based chemotherapy improves the response rate of R/R ENKL. However, no studies have yet reported that L-asparaginase has a synergistic effect with anti-PD-1 or demethylated drugs.

CONCLUSION

The experience of this case offers a new option for the treatment of R/R ENKL resistant to anti-PD-1 and other types of lymphomas. This case is only an empirical report of a single case, and the efficacy of decitabine combined with anti-PD-1 in R/R ENKL needs to be confirmed in more patients.
REFERENCES


FOOTNOTES

Author contributions: Zhang JY designed the report and wrote the paper; Li LJ collected the patient’s clinical data; all authors have read and approved the final version of this manuscript.

Supported by: the Medical Health Science and Technology Project of Zhejiang Province Health Commission, No. 2020376298.

Informed consent statement: Informed written consent was obtained from the patient for the publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Lin-Jie Li 0000-0003-2674-2996; Jun-Yu Zhang 0000-0002-1013-8172.

S-Editor: Chen YL
L-Editor: Wang TQ
P-Editor: Chen YL


